Abstract
The Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). Therefore, establishment of response evaluation criteria solely devoted to HCC is needed urgently in clinical practice as well as in clinical trials of HCC treatment, such as molecular-targeted therapies, which cause necrosis of the tumor. The Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2015 by the Liver Cancer Study Group of Japan based on the 2009 version of RECICL, which was commonly used in Japan. Major revised points of the RECICL 2015 is to define the target lesions of two lesions per organ or three lesions per liver, up to a maximum of five lesions. The second revised point is that setting the timing at which the overall treatment response has been changed. The third point is that the definition of treatment effect 1 has been changed to more than 50% tumor enlargement, excluding the area of necrosis after treatment. Overall evaluation of treatment response has been amended to make it possible to evaluate the overall response including extrahepatic lesions by systemic therapy, which is similar to RECIST or modified RECIST. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit HCC treatment response evaluation in the setting of daily clinical practice and clinical trials, not only in Japan, but also internationally.
| Original language | English |
|---|---|
| Pages (from-to) | 3-9 |
| Number of pages | 7 |
| Journal | Hepatology Research |
| Volume | 46 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2016 Jan 1 |
| Externally published | Yes |
Fingerprint
Keywords
- Hepatocellular carcinoma
- Liver Cancer Study Group of Japan
- Modified Response Evaluation Criteria in Solid Tumors
- Response Evaluation Criteria in Cancer of the Liver
- Response Evaluation Criteria in Solid Tumors
ASJC Scopus subject areas
- Hepatology
- Infectious Diseases
Cite this
Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version). / for the Liver Cancer Study Group of Japan.
In: Hepatology Research, Vol. 46, No. 1, 01.01.2016, p. 3-9.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version)
AU - for the Liver Cancer Study Group of Japan
AU - Kudo, Masatoshi
AU - Ueshima, Kazuomi
AU - Kubo, Shoji
AU - Sakamoto, Michiie
AU - Tanaka, Masatoshi
AU - Ikai, Iwao
AU - Furuse, Junji
AU - Murakami, Takamichi
AU - Kadoya, Masumi
AU - Kokudo, Norihiro
PY - 2016/1/1
Y1 - 2016/1/1
N2 - The Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). Therefore, establishment of response evaluation criteria solely devoted to HCC is needed urgently in clinical practice as well as in clinical trials of HCC treatment, such as molecular-targeted therapies, which cause necrosis of the tumor. The Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2015 by the Liver Cancer Study Group of Japan based on the 2009 version of RECICL, which was commonly used in Japan. Major revised points of the RECICL 2015 is to define the target lesions of two lesions per organ or three lesions per liver, up to a maximum of five lesions. The second revised point is that setting the timing at which the overall treatment response has been changed. The third point is that the definition of treatment effect 1 has been changed to more than 50% tumor enlargement, excluding the area of necrosis after treatment. Overall evaluation of treatment response has been amended to make it possible to evaluate the overall response including extrahepatic lesions by systemic therapy, which is similar to RECIST or modified RECIST. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit HCC treatment response evaluation in the setting of daily clinical practice and clinical trials, not only in Japan, but also internationally.
AB - The Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). Therefore, establishment of response evaluation criteria solely devoted to HCC is needed urgently in clinical practice as well as in clinical trials of HCC treatment, such as molecular-targeted therapies, which cause necrosis of the tumor. The Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2015 by the Liver Cancer Study Group of Japan based on the 2009 version of RECICL, which was commonly used in Japan. Major revised points of the RECICL 2015 is to define the target lesions of two lesions per organ or three lesions per liver, up to a maximum of five lesions. The second revised point is that setting the timing at which the overall treatment response has been changed. The third point is that the definition of treatment effect 1 has been changed to more than 50% tumor enlargement, excluding the area of necrosis after treatment. Overall evaluation of treatment response has been amended to make it possible to evaluate the overall response including extrahepatic lesions by systemic therapy, which is similar to RECIST or modified RECIST. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit HCC treatment response evaluation in the setting of daily clinical practice and clinical trials, not only in Japan, but also internationally.
KW - Hepatocellular carcinoma
KW - Liver Cancer Study Group of Japan
KW - Modified Response Evaluation Criteria in Solid Tumors
KW - Response Evaluation Criteria in Cancer of the Liver
KW - Response Evaluation Criteria in Solid Tumors
UR - http://www.scopus.com/inward/record.url?scp=84959339484&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959339484&partnerID=8YFLogxK
U2 - 10.1111/hepr.12542
DO - 10.1111/hepr.12542
M3 - Article
AN - SCOPUS:84959339484
VL - 46
SP - 3
EP - 9
JO - Hepatology Research
JF - Hepatology Research
SN - 1386-6346
IS - 1
ER -